Indications for: DELZICOL
Mildly to moderately active ulcerative colitis (UC) in patients ≥5 years of age. Maintenance of remission of UC in adults.
Swallow caps whole; if unable to swallow, may open and swallow contents (four 100mg tabs). Treatment: 800mg 3 times daily for 6 weeks. Maintenance: 1.6g/day in 2–4 divided doses. Two Delzicol 400mg caps are not bioequivalent to one mesalamine 800mg del-rel tab.
<5yrs: not established. Give twice daily dosing for 6 weeks. ≥5yrs (17–32kg): 36–71mg/kg/day, up to max 1.2g/day (800mg in the AM + 400mg in the afternoon); (33–53kg): 37–61mg/kg/day, up to max 2g/day (1200mg in the AM + 800mg in the afternoon); (54–90kg): 27–44mg/kg/day, up to max 2.4g/day (1200mg in the AM + 1200mg in the afternoon).
Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Consider iron content of Delzicol in those taking iron supplementation or at risk of iron overload. Renal or hepatic impairment. Monitor renal function prior to and periodically during therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.
Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine; consider other alternative assay.
Eructation, abdominal pain, constipation, dizziness, rhinitis, back pain, rash, dyspepsia, flu syndrome; acute intolerance syndrome, hypersensitivity reactions (including myocarditis, pericarditis, pneumonitis, hematologic abnormalities, others). Pediatrics: also, nasopharyngitis, headache, sinusitis, cough, diarrhea, fatigue, pyrexia, increased lipase.
Generic Drug Availability: